Identify Patients

In asymptomatic or minimally symptomatic mCRPC patients, treat them early with PROVENGE Immunotherapy

6 month duration

Treat early

  • To stimulate your mCRPC patients’ immune systems while they have a lower tumor burden1

NCCN category 1 recommendation

  • NCCN guidelines maintain PROVENGE as a first-line treatment and a prominent category 1 designation2
  • NCCN guidelines support the use of PROVENGE before enzalutamide, abiraterone, chemotherapy, and other treatments in asymptomatic or minimally symptomatic mCRPC patients2

PROVENGE does not preclude the use of subsequent therapies2,3

*Radiographic evidence of disease progression or rising prostate-specific antigen (PSA).
ADT=androgen deprivation therapy; mCRPC=metastatic castrate-resistant prostate cancer; NCCN=National Comprehensive Cancer Network.

Most CRPC patients fit in the PROVENGE window at the time of metastatic diagnosis

6 month duration

Treat early — make sure your patients take advantage of the PROVENGE window

Keep in mind that if your patient:

Candidate for Provenge

He may be a candidate for PROVENGE3

*Radiographic evidence of disease progression or rising PSA.

Learn about Mike's Experience with PROVENGE